JP7539902B2 - グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用 - Google Patents

グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用 Download PDF

Info

Publication number
JP7539902B2
JP7539902B2 JP2021546056A JP2021546056A JP7539902B2 JP 7539902 B2 JP7539902 B2 JP 7539902B2 JP 2021546056 A JP2021546056 A JP 2021546056A JP 2021546056 A JP2021546056 A JP 2021546056A JP 7539902 B2 JP7539902 B2 JP 7539902B2
Authority
JP
Japan
Prior art keywords
glp1
gdf15
fusion protein
peptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513363A5 (cg-RX-API-DMAC10.html
JP2022513363A (ja
Inventor
エム. ランキン,マシュー
リン-シュミット,シェファン
ファン,チチ
ファーマン,ジェニファー
ジェン,ソンマオ
ラングワラ,シャミナ
エム. ネルソン,セレーナ
マリカン,シャノン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70330680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7539902(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022513363A publication Critical patent/JP2022513363A/ja
Publication of JP2022513363A5 publication Critical patent/JP2022513363A5/ja
Priority to JP2024135217A priority Critical patent/JP2024170428A/ja
Application granted granted Critical
Publication of JP7539902B2 publication Critical patent/JP7539902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021546056A 2018-10-22 2019-10-22 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用 Active JP7539902B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135217A JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
US62/748,603 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135217A Division JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022513363A JP2022513363A (ja) 2022-02-07
JP2022513363A5 JP2022513363A5 (cg-RX-API-DMAC10.html) 2022-10-27
JP7539902B2 true JP7539902B2 (ja) 2024-08-26

Family

ID=70330680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546056A Active JP7539902B2 (ja) 2018-10-22 2019-10-22 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド1(glp1)-増殖分化因子15(gdf15)融合タンパク質及びその使用

Country Status (24)

Country Link
US (3) US11713345B2 (cg-RX-API-DMAC10.html)
EP (2) EP4520343A3 (cg-RX-API-DMAC10.html)
JP (2) JP7539902B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210081389A (cg-RX-API-DMAC10.html)
CN (2) CN119751697A (cg-RX-API-DMAC10.html)
AU (2) AU2019368816B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021007376A2 (cg-RX-API-DMAC10.html)
CA (1) CA3116983A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021000987A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021005051A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210193A (cg-RX-API-DMAC10.html)
DO (1) DOP2021000075A (cg-RX-API-DMAC10.html)
EA (1) EA202191105A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP21028914A (cg-RX-API-DMAC10.html)
ES (1) ES3011982T3 (cg-RX-API-DMAC10.html)
IL (1) IL282297B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20210084A1 (cg-RX-API-DMAC10.html)
MX (1) MX428581B (cg-RX-API-DMAC10.html)
MY (1) MY205905A (cg-RX-API-DMAC10.html)
PE (1) PE20211078A1 (cg-RX-API-DMAC10.html)
PH (1) PH12021550885A1 (cg-RX-API-DMAC10.html)
SA (1) SA521421825B1 (cg-RX-API-DMAC10.html)
SG (1) SG11202103990QA (cg-RX-API-DMAC10.html)
WO (1) WO2020084496A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) * 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
JP7536030B2 (ja) * 2019-03-08 2024-08-19 アムジエン・インコーポレーテツド 増殖分化因子15併用療法
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
EP4351627A4 (en) * 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
AU2022278933A1 (en) * 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
EP4619423A1 (en) * 2022-11-18 2025-09-24 Yuhan Corporation Dual function proteins and uses thereof
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Gfralを標的にするアンチセンスオリゴマー及びこの用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US20080044411A1 (en) 2006-07-18 2008-02-21 O'neil Karyn T Human glp-1 mimetibodies, compositions, methods and uses
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
CA2740632A1 (en) 2008-10-31 2010-05-06 St. Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
MX2011007889A (es) 2009-02-06 2011-08-15 Syngenta Participations Ag Modificacion de enzima multidominio para la expresion en plantas.
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
EP2456454A4 (en) 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
WO2012091564A2 (en) 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
AU2014283221A1 (en) * 2013-06-20 2015-12-03 Novo Nordisk A/S GLP-1 derivatives and uses thereof
LT3027642T (lt) * 2013-07-31 2020-10-12 Amgen Inc. Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015197446A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
CN106687128B (zh) 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Gfral受容体療法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
WO2018071493A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
CN113474363A (zh) 2018-11-20 2021-10-01 詹森药业有限公司 用于降低体重和/或减少食物摄取量的gdf15类似物和方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US20080044411A1 (en) 2006-07-18 2008-02-21 O'neil Karyn T Human glp-1 mimetibodies, compositions, methods and uses
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof

Also Published As

Publication number Publication date
EA202191105A1 (ru) 2021-08-03
EP3870211B1 (en) 2025-01-08
KR20210081389A (ko) 2021-07-01
US11713345B2 (en) 2023-08-01
CN113226351A (zh) 2021-08-06
BR112021007376A2 (pt) 2021-08-10
CL2021000987A1 (es) 2021-09-10
CA3116983A1 (en) 2020-04-30
CO2021005051A2 (es) 2021-04-30
JP2022513363A (ja) 2022-02-07
PH12021550885A1 (en) 2022-02-21
IL282297A (en) 2021-05-31
MX428581B (es) 2025-11-13
CN113226351B (zh) 2025-01-14
AU2025203071A1 (en) 2025-05-22
SA521421825B1 (ar) 2024-03-06
EP3870211C0 (en) 2025-01-08
WO2020084496A1 (en) 2020-04-30
SG11202103990QA (en) 2021-05-28
DOP2021000075A (cg-RX-API-DMAC10.html) 2021-12-15
JOP20210084A1 (ar) 2021-04-22
EP4520343A3 (en) 2025-05-21
MX2021004665A (es) 2021-08-24
US20250197468A1 (en) 2025-06-19
US12275770B2 (en) 2025-04-15
IL282297B1 (en) 2026-04-01
AU2019368816B2 (en) 2025-01-30
US20230322888A1 (en) 2023-10-12
PE20211078A1 (es) 2021-06-09
JP2024170428A (ja) 2024-12-10
ES3011982T3 (en) 2025-04-08
IL282297B2 (en) 2026-08-01
MY205905A (en) 2024-11-20
AU2019368816A1 (en) 2021-05-13
CN119751697A (zh) 2025-04-04
EP3870211A4 (en) 2022-08-10
EP4520343A2 (en) 2025-03-12
CR20210193A (es) 2021-06-15
ECSP21028914A (es) 2021-05-31
US20220089669A1 (en) 2022-03-24
EP3870211A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
US12275770B2 (en) Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
KR102865076B1 (ko) 글루카곤-유사 펩티드 1(glp-1) 융합 펩티드 커플링된 사이클릭 펩티드 티로신 티로신 접합체 및 이의 용도
US20110195896A1 (en) Isoform-specific insulin analogues
US20240117000A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
HK40120308A (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
HK40060006A (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
EA050724B1 (ru) Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
HK40060006B (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
HK40045710B (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
HK40045710A (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240814

R150 Certificate of patent or registration of utility model

Ref document number: 7539902

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150